| Type II diabetes mellitus |
1.84 |
1.31e-1 |
42/46 (91.3%) |
PRKCD;ADIPOQ;CACNA1A;...
|
| Arrhythmogenic right ventricular cardiomyopathy |
1.77 |
1.84e-1 |
70/77 (90.91%) |
DSP;ATP2A3;ITGAV;...
|
| Nicotine addiction |
1.76 |
1.23e-1 |
32/40 (80%) |
GRIA2;GABRE;CACNA1A;...
|
| Pyrimidine metabolism |
1.72 |
1.42e-1 |
40/56 (71.43%) |
CANT1;CDA;ENTPD4;...
|
| Cardiac muscle contraction |
1.71 |
1.31e-1 |
64/87 (73.56%) |
ATP2A3;TNNC1;CACNB4;...
|
| Dilated cardiomyopathy |
1.64 |
1.76e-1 |
86/96 (89.58%) |
GNAS;ATP2A3;TNNC1;...
|
| Taurine and hypotaurine metabolism |
1.56 |
3.19e-1 |
8/11 (72.73%) |
ADO;CSAD;GGT5
|
| Steroid biosynthesis |
1.54 |
3.25e-1 |
19/20 (95%) |
LSS;SQLE;MSMO1;...
|
| Base excision repair |
1.53 |
2.99e-1 |
29/33 (87.88%) |
OGG1;PCNA;APEX2;...
|
| Fc gamma R-mediated phagocytosis |
1.53 |
2.88e-1 |
79/97 (81.44%) |
PRKCD;MARCKS;LIMK2;...
|
| Central carbon metabolism in cancer |
1.49 |
3.78e-1 |
67/70 (95.71%) |
SLC7A5;SLC2A1;SIRT3;...
|
| Viral protein interaction with cytokine and cytokine re... |
1.49 |
3.49e-1 |
84/100 (84%) |
CXCL9;CCL19;CXCL13;...
|
| Hypertrophic cardiomyopathy |
1.48 |
3.41e-1 |
81/90 (90%) |
ATP2A3;TNNC1;ITGAV;...
|
| Diabetic cardiomyopathy |
1.47 |
3.49e-1 |
162/203 (79.8%) |
PRKCD;PLCB4;SLC2A1;...
|
| Insulin signaling pathway |
1.40 |
5.26e-1 |
121/137 (88.32%) |
MKNK1;SHC1;PYGB;...
|
| Insulin secretion |
1.22 |
5.59e-1 |
75/86 (87.21%) |
GNAS;PLCB4;SLC2A1;...
|
| Acute myeloid leukemia |
1.22 |
5.63e-1 |
66/67 (98.51%) |
MPO;LEF1;CD14;...
|
| Salmonella infection |
1.21 |
5.55e-1 |
198/249 (79.52%) |
S100A10;LEF1;ARPC4;...
|
| TGF-beta signaling pathway |
1.21 |
5.55e-1 |
81/94 (86.17%) |
ID1;E2F5;INHBB;...
|
| Protein digestion and absorption |
1.18 |
5.58e-1 |
78/103 (75.73%) |
CPA3;KCNN4;COL11A1;...
|
| Mannose type O-glycan biosynthesis |
1.15 |
5.59e-1 |
14/23 (60.87%) |
FKTN;B3GAT1;POMGNT1;...
|
| Glucagon signaling pathway |
1.15 |
5.62e-1 |
89/107 (83.18%) |
GNAS;PLCB4;SLC2A1;...
|
| Wnt signaling pathway |
1.15 |
5.57e-1 |
124/166 (74.7%) |
PLCB4;LEF1;PRKCA;...
|
| Relaxin signaling pathway |
1.15 |
5.48e-1 |
114/129 (88.37%) |
GNAS;PLCB4;MMP9;...
|
| ECM-receptor interaction |
1.15 |
5.47e-1 |
80/88 (90.91%) |
ITGAV;LAMB3;ITGB4;...
|
| Amoebiasis |
1.14 |
5.56e-1 |
99/102 (97.06%) |
GNAS;PLCB4;LAMB3;...
|
| Vasopressin-regulated water reabsorption |
1.14 |
5.58e-1 |
40/44 (90.91%) |
GNAS;DYNC2H1;DYNC1I1;...
|
| Osteoclast differentiation |
1.14 |
5.59e-1 |
117/127 (92.13%) |
RELB;BLNK;SOCS1;...
|
| NF-kappa B signaling pathway |
1.14 |
5.55e-1 |
90/104 (86.54%) |
RELB;CCL19;BLNK;...
|
| Gastric cancer |
1.13 |
5.56e-1 |
122/149 (81.88%) |
SHC1;LEF1;FZD5;...
|
| Drug metabolism |
-1.31 |
3.49e-1 |
78/151 (51.66%) |
FMO2;FMO4;IMPDH2;...
|
| TNF signaling pathway |
-1.31 |
3.46e-1 |
103/112 (91.96%) |
FADD;MAP2K3;ATF4;...
|
| Fluid shear stress and atherosclerosis |
-1.34 |
3.49e-1 |
123/139 (88.49%) |
CAV2;JUN;FOS;...
|
| Folate biosynthesis |
-1.35 |
3.23e-1 |
23/26 (88.46%) |
AKR1B1;PTS;AKR1C3;...
|
| Viral carcinogenesis |
-1.37 |
3.11e-1 |
149/203 (73.4%) |
UBE3A;HNRNPK;HLA-A;...
|
| Glycine, serine and threonine metabolism |
-1.37 |
3.13e-1 |
31/40 (77.5%) |
BHMT;PSAT1;AGXT;...
|
| Staphylococcus aureus infection |
-1.38 |
3.11e-1 |
72/95 (75.79%) |
FCGR3B;CFD;KRT38;...
|
| Citrate cycle (TCA cycle) |
-1.38 |
3.22e-1 |
30/30 (100%) |
IDH2;DLST;OGDHL;...
|
| Metabolism of xenobiotics by cytochrome P450 |
-1.39 |
3.17e-1 |
49/77 (63.64%) |
CYP2A6;GSTM5;ADH1B;...
|
| Cholesterol metabolism |
-1.39 |
3.22e-1 |
44/50 (88%) |
APOC3;VDAC2;SOAT1;...
|
| Protein export |
-1.39 |
3.32e-1 |
17/23 (73.91%) |
SRPRB;SEC61B;SRP72;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
-1.39 |
3.44e-1 |
62/70 (88.57%) |
PTPRZ1;MAPK8;ATP6V0A2;...
|
| Tyrosine metabolism |
-1.40 |
3.47e-1 |
30/36 (83.33%) |
TYRP1;ADH1B;MAOA;...
|
| Steroid hormone biosynthesis |
-1.42 |
3.39e-1 |
43/61 (70.49%) |
HSD17B6;CYP11B2;HSD17B12;...
|
| Mineral absorption |
-1.46 |
2.83e-1 |
48/60 (80%) |
SLC31A1;MT1G;ATP1A1;...
|
| Phagosome |
-1.48 |
2.53e-1 |
118/152 (77.63%) |
TUBB;FCGR3B;STX18;...
|
| Antigen processing and presentation |
-1.49 |
2.42e-1 |
60/78 (76.92%) |
CREB1;CD74;CTSS;...
|
| Legionellosis |
-1.50 |
2.44e-1 |
51/57 (89.47%) |
TNF;IL6;SAR1A;...
|
| Autoimmune thyroid disease |
-1.50 |
2.60e-1 |
46/53 (86.79%) |
HLA-A;CGA;HLA-DRA;...
|
| Rheumatoid arthritis |
-1.51 |
2.57e-1 |
78/93 (83.87%) |
CXCL12;ANGPT1;HLA-DPB1;...
|
| Kaposi sarcoma-associated herpesvirus infection |
-1.52 |
2.67e-1 |
172/193 (89.12%) |
RCAN1;HLA-A;IFNB1;...
|
| Lysosome |
-1.57 |
1.90e-1 |
115/128 (89.84%) |
CTSZ;AP3S2;M6PR;...
|
| Graft-versus-host disease |
-1.57 |
1.96e-1 |
32/42 (76.19%) |
HLA-DPB1;IL1A;HLA-G;...
|
| Type I diabetes mellitus |
-1.58 |
2.17e-1 |
38/43 (88.37%) |
HLA-A;HLA-DRA;HSPD1;...
|
| Histidine metabolism |
-1.58 |
2.47e-1 |
16/22 (72.73%) |
MAOA;ASPA;ALDH2;...
|
| Complement and coagulation cascades |
-1.59 |
2.76e-1 |
76/85 (89.41%) |
F2R;PROCR;CFD;...
|
| Allograft rejection |
-1.69 |
1.49e-1 |
32/38 (84.21%) |
HLA-G;HLA-E;HLA-C;...
|
| Pertussis |
-1.76 |
9.09e-2 |
64/76 (84.21%) |
GNAI3;TNF;C5;...
|
| Viral myocarditis |
-1.78 |
1.28e-1 |
53/60 (88.33%) |
LAMA2;FYN;SGCB;...
|
| Retinol metabolism |
-1.80 |
2.04e-1 |
41/68 (60.29%) |
HSD17B6;DHRS9;CYP2A6;...
|
